Article

353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

2024-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4182172-3eee-5739-ba25-26840774d21c
DOI: 10.1016/j.annonc.2024.08.301

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2DOI 10.1016/j.annonc.2024.08.301Read

263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)Semantic proximity Read

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trialSemantic proximity Read

Germline mutations in PALB2 in African-American breast cancer casesSemantic proximity Read

Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapySemantic proximity Read

Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.Semantic proximity Read

Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.Semantic proximity Read

Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.Semantic proximity Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK studySemantic proximity Read

Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.Semantic proximity Read

Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.Semantic proximity Read